244 related articles for article (PubMed ID: 20670131)
41. Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney.
Liao SY; Aurelio ON; Jan K; Zavada J; Stanbridge EJ
Cancer Res; 1997 Jul; 57(14):2827-31. PubMed ID: 9230182
[TBL] [Abstract][Full Text] [Related]
42. The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: a comparative study.
Ordóñez NG
Hum Pathol; 2004 Jun; 35(6):697-710. PubMed ID: 15188136
[TBL] [Abstract][Full Text] [Related]
43. The use of immunohistochemistry in the diagnosis of metastatic clear cell renal cell carcinoma: a review of PAX-8, PAX-2, hKIM-1, RCCma, and CD10.
Sangoi AR; Karamchandani J; Kim J; Pai RK; McKenney JK
Adv Anat Pathol; 2010 Nov; 17(6):377-93. PubMed ID: 20966644
[TBL] [Abstract][Full Text] [Related]
44. Expression analysis of kidney-specific cadherin in a wide spectrum of traditional and newly recognized renal epithelial neoplasms: diagnostic and histogenetic implications.
Kuehn A; Paner GP; Skinnider BF; Cohen C; Datta MW; Young AN; Srigley JR; Amin MB
Am J Surg Pathol; 2007 Oct; 31(10):1528-33. PubMed ID: 17895753
[TBL] [Abstract][Full Text] [Related]
45. Pax8, Napsin A, and CD10 as Immunohistochemical Markers of Canine Renal Cell Carcinoma.
Peat TJ; Edmondson EF; Miller MA; DuSold DM; Ramos-Vara JA
Vet Pathol; 2017 Jul; 54(4):588-594. PubMed ID: 28346124
[TBL] [Abstract][Full Text] [Related]
46. PAX2 and PAX8: useful markers for metastatic effusions.
Waters L; Crumley S; Truong L; Mody D; Coffey D
Acta Cytol; 2014; 58(1):60-6. PubMed ID: 24334997
[TBL] [Abstract][Full Text] [Related]
47. [Expression and clinical significance of kidney injury molecule-1 in renal epithelial neoplasms].
Dong YC; Wu B; Wang JD; Rao Q; Ma HH; Zhang RS; Zhou HB; Lu ZF; Zhou XJ
Zhonghua Bing Li Xue Za Zhi; 2010 Jan; 39(1):35-9. PubMed ID: 20388397
[TBL] [Abstract][Full Text] [Related]
48. [Expression of Ksp-cadherin in renal epithelial neoplasm and its clinicopathologic significance].
Rao Q; Zhou XJ; Shi QL; Yin HL; Ma HH; Zhou HB; Zhang RS
Zhonghua Bing Li Xue Za Zhi; 2007 Jan; 36(1):15-8. PubMed ID: 17374232
[TBL] [Abstract][Full Text] [Related]
49. The utility of tetraspanin CD9 as a biomarker for metastatic clear cell renal cell carcinoma.
Garner JM; Herr MJ; Hodges KB; Jennings LK
Biochem Biophys Res Commun; 2016 Feb; 471(1):21-5. PubMed ID: 26855131
[TBL] [Abstract][Full Text] [Related]
50. Expression of Galectin-3 in renal neoplasms: a diagnostic, possible prognostic marker.
Dancer JY; Truong LD; Zhai Q; Shen SS
Arch Pathol Lab Med; 2010 Jan; 134(1):90-4. PubMed ID: 20073610
[TBL] [Abstract][Full Text] [Related]
51. Co-existence of epithelioid and fibroblastoid subsets in a sarcomatoid renal carcinoma cell line revealed by clonal studies.
Hsieh CH; Chen HC; Chang YH; Pang ST; Kuo ML; Chuang CK; Liao SK
Anticancer Res; 2013 Nov; 33(11):4875-89. PubMed ID: 24222125
[TBL] [Abstract][Full Text] [Related]
52. Caution in metastatic renal cell carcinoma within lymph nodes: PAX-2 expression is also seen in nodal lymphocytes.
Gilmore L; Dewar R
Arch Pathol Lab Med; 2011 Apr; 135(4):414; author reply 414-5. PubMed ID: 21466350
[No Abstract] [Full Text] [Related]
53. Deregulation of PAX2 expression in renal cell tumours: mechanisms and potential use in differential diagnosis.
Patrício P; Ramalho-Carvalho J; Costa-Pinheiro P; Almeida M; Barros-Silva JD; Vieira J; Dias PC; Lobo F; Oliveira J; Teixeira MR; Henrique R; Jeronimo C
J Cell Mol Med; 2013 Aug; 17(8):1048-58. PubMed ID: 23890189
[TBL] [Abstract][Full Text] [Related]
54. Role Of Immunohistochemistry In Subtyping Renal Cell Carcinomas With Overlapping Morphological Features.
Tariq N; Mamoon N; Haroon A; Ali Z; Ahmad IN
J Ayub Med Coll Abbottabad; 2018; 30(3):325-332. PubMed ID: 30465359
[TBL] [Abstract][Full Text] [Related]
55. Expanding the morphologic spectrum of chromophobe renal cell carcinoma: A study of 8 cases with papillary architecture.
Michalova K; Tretiakova M; Pivovarcikova K; Alaghehbandan R; Perez Montiel D; Ulamec M; Osunkoya A; Trpkov K; Yuan G; Grossmann P; Sperga M; Ferak I; Rogala J; Mareckova J; Pitra T; Kolar J; Michal M; Hes O
Ann Diagn Pathol; 2020 Feb; 44():151448. PubMed ID: 31918172
[TBL] [Abstract][Full Text] [Related]
56. Chromophobe renal cell carcinoma: an immunohistochemical study of 21 Japanese cases.
Taki A; Nakatani Y; Misugi K; Yao M; Nagashima Y
Mod Pathol; 1999 Mar; 12(3):310-7. PubMed ID: 10102617
[TBL] [Abstract][Full Text] [Related]
57. Vascular cell adhesion molecule 1 predicts cancer-free survival in clear cell renal carcinoma patients.
Shioi K; Komiya A; Hattori K; Huang Y; Sano F; Murakami T; Nakaigawa N; Kishida T; Kubota Y; Nagashima Y; Yao M
Clin Cancer Res; 2006 Dec; 12(24):7339-46. PubMed ID: 17189405
[TBL] [Abstract][Full Text] [Related]
58. Paxillin: application of immunohistochemistry to the diagnosis of chromophobe renal cell carcinoma and oncocytoma.
Kuroda N; Guo L; Toi M; Naruse K; Miyazaki E; Hayashi Y; Yoshikawa C; Ashida S; Shuin T; Enzan H
Appl Immunohistochem Mol Morphol; 2001 Dec; 9(4):315-8. PubMed ID: 11759057
[TBL] [Abstract][Full Text] [Related]
59. Clear cell meningioma: a clinicopathologic study of 18 tumors and examination of the use of CD10, CA9, and RCC antibodies to distinguish between clear cell meningioma and metastatic clear cell renal cell carcinoma.
Prayson RA; Chamberlain WA; Angelov L
Appl Immunohistochem Mol Morphol; 2010 Oct; 18(5):422-8. PubMed ID: 20453815
[TBL] [Abstract][Full Text] [Related]
60. Enhancer of zeste homolog 2 expression is associated with metastasis and adverse clinical outcome in clear cell renal cell carcinoma: a comparative study and review of the literature.
Xu B; Abourbih S; Sircar K; Kassouf W; Mansure JJ; Aprikian A; Tanguay S; Brimo F
Arch Pathol Lab Med; 2013 Oct; 137(10):1326-36. PubMed ID: 24079759
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
